SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Cavorsi Robert (Last) (First) (Middle) C/O ORGANOGENESIS HOLDINGS INC. 85 DAN ROAD (Street) CANTON MA 02021 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 04/19/2024	3. Issuer Name and Ticker or Trading Symbol Organogenesis Holdings Inc. [ ORGO ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Vice President, Strategy	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Class A Common Stock	23,579(2)	D
Class A Common Stock(1)	739(3)	D
Class A Common Stock(1)	215(3)	D
Class A Common Stock(1)	2,163(4)	D
Class A Common Stock(1)	4,203(5)	D
Class A Common Stock(1)	51,750(6)	D
Class A Common Stock(1)	57,434(7)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(8)	03/09/2031	Class A Common Stock	6,519	15.63	D
Stock Option (Right to Buy)	(9)	07/16/2031	Class A Common Stock	32,559	14.45	D
Stock Option (Right to Buy)	(10)	03/01/2032	Class A Common Stock	19,935	8.03	D
Stock Option (Right to Buy)	(11)	03/15/2033	Class A Common Stock	81,000	2.51	D
Stock Option (Right to Buy)	(12)	02/21/2034	Class A Common Stock	103,842	3.43	D

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock.

2. Represents shares of Class A Common Stock of Organogenesis pursuant to vested RSUs under the 2018 Equity Incentive Plan.

3. The RSUs vest in equal annual installments over four years beginning March 9, 2021, and shall become fully vested on March 9, 2025.

4. The RSUs vest in equal annual installments over four years beginning July 16, 2021, and shall become fully vested on July 16, 2025.

5. The RSUs vest in equal annual installments over four years beginning March 1, 2022, and shall become fully vested on March 1, 2026.

6. The RSUs vest in equal annual installments over four years beginning February 15, 2023, and shall become fully vested on February 15, 2027.

7. The RSUs vest in equal annual installments over four years beginning February 15, 2024, and shall become fully vested on February 15, 2028.

8. The option becomes exercisable in equal annual installments over four years beginning March 9, 2021, and shall become fully vested and exercisable on March 9, 2025.

9. The option becomes exercisable in equal annual installments over four years beginning July 16, 2021, and shall become fully vested and exercisable on July 16, 2025.

10. The option becomes exercisable in equal annual installments over four years beginning March 1, 2022, and shall become fully vested and exercisable on March 1, 2026.

11. The option becomes exercisable in equal annual installments over four years beginning February 15, 2023, and shall become fully vested and exercisable on February 15, 2027.

12. The option becomes exercisable in equal annual installments over four years beginning February 15, 2024, and shall become fully vested and exercisable on February 15, 2028.

Remarks:

Exhibit 24 Power of Attorney filed herewith.

	/s/ William R. Kolb, Attorney-in-Fact	04/29/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY
     KNOW ALL BY THESE PRESENTS, that the undersigned hereby authorizes
Lori Freedman, William R. Kolb, Stacie S. Aarestad and Ryan M. Rourke Reed,
each acting singly, to execute and caused to be filed with the United States
Securities and Exchange Commission any and all documents or filings,
including any amendments thereto, required to be so filed. The undersigned
hereby grants to the attorney-in-fact full power and authority to do and
perform any and every act and thing whatsoever requisite, necessary or proper
to be done in the exercise of any of the rights and powers herein granted,
as fully to all intents and purposes as the undersigned might or could do
personally present, with full power of substitution, resubstitution or
revocation, hereby ratifying and confirming all that such attorney-in-fact,
or such attorney's-in-fact substitute or substitutes, shall lawfully do or
cause to be done by virtue of this power of attorney and the rights and
powers herein granted. The undersigned acknowledges that the foregoing
attorney-in-fact, in serving in such capacity at the request of the
undersigned, is not assuming any of the undersigned's responsibilities
to comply with all applicable laws, including Sections 13 and 16 of the
Securities Exchange Act of 1934.

     This Power of Attorney shall remain in full force and effect until
revoked by the undersigned in a signed writing delivered to the
foregoing attorney-in-fact.

     IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of this 22nd day of April, 2024.

/s/ Robert Cavorsi
Name: Robert Cavorsi